Letter by Ng et al Regarding Article, "Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial"

Circulation. 2022 Mar 22;145(12):e773-e774. doi: 10.1161/CIRCULATIONAHA.121.057407. Epub 2022 Mar 21.

Authors

Chi Fai Ng¹, Jeremy Y C Teoh¹, Peter K F Chiu¹

Affiliation

¹ The Chinese University of Hong Kong, China.

PMID: 35312383
DOI: 10.1161/CIRCULATIONAHA.121.057407

No abstract available

Publication types

Letter
Comment

MeSH terms

Cardiovascular System*
Humans
Leuprolide / adverse effects
Male
Oligopeptides
Prostatic Neoplasms* / drug therapy

Substances

Oligopeptides
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
Leuprolide